Coupling of dopamine receptor subtypes to multiple and diverse G proteins

International Journal of Developmental Neuroscience

Volumn 18, Issue 7, 2000, Pages 669-677

  Sidhu, Anita ^a   Niznik, Hyman B ^b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Dopamine receptors; G proteins; Parkinson's disease; Schizophrenia; Signal transduction

Indexed keywords

ADENYLATE CYCLASE; DOPAMINE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; RECEPTOR SUBTYPE;

ATTENTION DEFICIT DISORDER; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0033848928     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(00)00033-2     Document Type: Article

References (86)

1. Apostolakis E.M., Garai J., Clark J.H., O'Malley B.W. In vivo regulation of central neurous system progesterone receptors: cocaine induces steroid dependent behavior through dopamine transporter modulation of D5 receptors in rats. Mol. Endocrinol. 10:1996;1595-1604.
2. Ariano M.A., Drago J., Sibley D.R., Levine M.S. Striatal excitatory amino acid receptor subunit expression in the D1a receptor deficient mouse. Dev. Neurosci. 20:1998;237-241.
3. Arrigo P., Fariselli P., Casadio R. Can functional regions of proteins be predicted from their coding sequences? The case study of G-protein coupled receptors. Gene. 221:1998;GC65-GC110.
4. Baldessarini R.J. Dopamine receptors and clinical medicine. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;457-498 Humana Press, NJ.
5. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Revs. Neurobiol. 12:1998;37-63.
6. Beninger R.J., Miller R. Dopamine D1 like receptors and reward related incentive learning. Neurosci. Biobehav. Revs. 22:1998;335-345.
7. +-ATPase activity in neostriatal neurons through D1 and D2 receptor synergism. Nature. 347:1990;386-388.
8. Choi E.Y., Jeong D., Won K., Park, Baik J.H. G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem. Biophys. Res. Commun. 256:1999;33-40.
9. Crawford C.A., Drago J., Watson J.B., Levine M.S. Effects of repeated amphetamine treatment on locomotor activity of the dopamine D1A deficient mouse. NeuroReport. 8:1997;2523-2527.
10. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 390:1997;88-91.
11. Dahmer M.K., Senogles S.E. Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors. J. Neurochem. 66:1996;222-232.
12. Drago J., Padungchaichot Accili P., Fuchs S. Dopamine receptors and dopamine transporter in brain function and addictive behaviors: insights from targeted mouse mutants. Dev. Neurosci. 20:1998;188-203.
13. 2+ current by the dopamine D1 receptor in rat adrenal glomerulosa cells: requirement of the combined action of the G betagamma protein subunit and cyclic adenosine 3′,5′-monophosphate. Mol. Endocrinol. 11:1997;503-514.
14. 2A-adrenergic receptor: localization of two redundant and fully competent coupling domains. J. Biol. Chem. 271:1996;12826-12832.
15. s coupling selectivity. J. Biol. Chem. 273:1998;26549-26558.
16. Exton J.H. Cell signaling through guanine-nucleotide-binding regulatory proteins (G proteins) and phospholipases. Eur. J. Biochem. 243:1997;10-20.
17. + exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am. J. Physiol. 259:1990;F297-F303.
18. Fields T.A., Casey P.J. Signalling functions and biochemical properties of pertussis toxin-resistant G proteins. Biochem. J. 321:1997;561-571.
19. Friedman E., Jin L.Q., Cai G.P., Hollon T.R., Drago J., Sibley D.R., Wang H.Y. D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Mol. Pharmacol. 51:1997;6-11.
20. i2. Biochemistry. 35:1996;15162-15173.
21. Hietala J., Syvalahti E. Dopamine in schizophrenia. Ann. of Med. 28:1996;557-561.
22. Hess E.J., Bracha H.S., Kleinman J.E., Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40:1987;1487-1497.
23. Hollerman J.R., Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat. Neurosci. 1:1998;304-309.
24. 2+ signal transduction pathways. J. Biol. Chem. 271:1996;33382-33389.
25. Hyman S.E. Addiction to cocaine and amphetamine. Neuron. 16:1996;901-904.
26. Iverson S.D. Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson's disease. Behav. Pharmacol. 6:1995;478-491.
27. Kimura K., Sela S., Bouvier C., Grandy D.K., Sidhu A. Differences in the bindingproperties of D-1 and D-5 dopamine receptors expressed in GH4Cl rat somatomammotrophic cells. J. Neurochem. 64:1995;2118-2124.
28. o. J. Biol. Chem. 270:1995;14672-14678.
29. Kuzhikandathil E.V., Oxford G.S. Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells. J. Neurosci. 19:1999;1698-1707.
30. + efflux in the chick retina via D1 receptors independently of adenylyl cyclase activation. J. Neurochem. 61:1993;1461-1469.
31. Lefkowitz R.J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14:1993;303-307.
32. Levine M.S., Altemus K.L., Cepeda C., Cromwell H.C., Crawford C., Ariano M.A., Drago J., Sibley D.R., Westphal H. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J. Neurosci. 16:1996;5870-5882.
33. Li L., Schafer J.A. Dopamine inhibits vasopressin-dependent cAMP production in the rat cortical collecting duct. Am. J. Physiol. 275:1998;F62-F67.
34. s. Requirement for multiple cytoplasmic domains in the coupling process. J. Biol. Chem. 266:1991;4816-4821.
35. Liu Y.F., Civelli O., Zhou Q.Y., Albert P.R. Cholera toxin-sensitive 3′,5′-cyclic adenosine monophosphate and calcium signals of the human dopamine-D1 receptor: selective potentiation by protein kinase A. Mol. Endocrinol. 6:1992;1815-1824.
36. i subtype specificity of the 5-HT1A receptor. J. Biol. Chem. 274:1999;16444-16450.
37. Liu L.X., Burgess L.H., Gonzalez A.M., Sibley D.R., Chiodo L.A. D2 S, D2L, D3 and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2×mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Synapse. 31:1999;108-118.
38. Liu F., Wan Q., Pristupa Z.B., Yu X.-M., Wang Y.T., Niznik H.B. Direct protein-protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors. Nature. 403:2000;274-280.
39. 2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. USA. 87:1990;2196-2200.
40. Matthies H., Becker A., Schroeder H., Kraus J., Hollt V., Krug M. Dopamine D1 deficient mutant mice do not express the late phase of hippocamal long term potentiation. NeuroReport. 8:1997;3533-3535.
41. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Revs. 78:1998;189-225.
42. Moratalla R., Xu M., Tonegawa S., Graybiel A.M. Proc. Natl. Acad. Sci. USA. 93:1996;14928-14933.
43. Neer E.J. G proteins: critical control points for transmembrane signals. ProteinSci. 3:1994;3-14.
44. Nestler E.J. Molecular mechanisms of opiate and cocaine addiction. Curr. Opin. Neurobiol. 7:1997;713-719.
45. Newman-Tancredi A., Cussac D., Audinot V., Pasteau V., Gavaudan S., Millan M.J. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′-O-(3-[35 Sγ]thio)-triphosphate binding and antibody study. Mol. Pharmacol. 55:1999;564-574.
46. Neve K.A., Neve R.L. Molecular biology of dopamine receptors. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;27-76 Humana Press, NJ.
47. Niznik H.B., Sugamori K.S., Clifford J.J., Waddington J.L. D1-like dopamine receptors: molecular biology and pharmacolgy. Di Chiara G. Handbook of Experimental Pharmacology - Dopamine in the CNS. 2000;Springer Verlag. (in press).
48. s. Cell. Mol. Neurobiol. 19:1999;653-664.
49. O'Dowd B.F. Structures of dopamine receptors. J. Neurochem. 60:1993;804-816.
50. i1, leading to the inhibition of adenylate cyclase in transfected cell lines. J. Pharmacol. Exp. Ther. 278:1996;354-360.
51. s. Analysis of chimeric A1/A2a adenosine receptors. J. Biol. Chem. 272:1997;337-344.
52. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature (London). 365:1993;649-651.
53. Picetti R., Saiardi A., Samad T.A., Bozzi Y., Baik J., Borrelli E. Dopamine D2 receptors in signal transduction and behavior. Crit. Rev. Neurobiol. 11:1997;121-142.
54. + channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology. 37:1998;983-987.
55. Piomelli D., Pilon C., Giros B., Sokoloff P., Martes M.P., Schwartz J.C. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature. 353:1991;164-167.
56. Reale V., Hannan F., Hall L.M., Evans P.D. Agonist-specific coupling of a cloned Drosophila melanogaster D1-like dopamine receptor to multiple second messenger pathways by synthetic agonists. J. Neurosci. 17:1997;6545-6553.
57. Rivkees S.A., Lachowicz J.E. Functional D1 and D5 dopamine receptors are expressed in the suprachiasmatic, supraoptic, and paraventricular nuclei of primates. Synapse. 26:1997;1-10.
58. Robinson S.W., Caron M.G. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol. Pharmacol. 52:1997;508-514.
59. Schiffmann S.N., Lledo P.M., Vincent J.D. Dopamine D1 receptor modulates the voltage-gated sodium current in rat striatal neurones through a protein kinase A. J. Physiol. (Lond). 483:1995;95-107.
60. Schultz W., Dayan P., Montague R.R. A neural substrate for prediction. Science. 275:1997;1593-1599.
61. Schwartz J.C., Diaz J., Bordet R., Griffon N., Perachon S., Pilon C., Ridray S., Sokoloff P. Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res. Brain Res. Rev. 26:1998;236-242.
62. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Becker L.E., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Watanabe S., et al. Human brain dopamine receptors in children and aging adults. Synapse. 1:1987;399-404.
63. Seeman P., Tallerico T., Corbett R., Van Tol H.H., Kamboj R.K. Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action. J. Psychopharmacol. 11:1997;15-17.
64. Self D.W., Barnhart W.J., Lehman D.A., Nestler E.J. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science. 271:1996;1586-1589.
65. Shenker A., Laue L., Kosugi S., Merendino J.J. Jr, Minegisha T., Cutler G.B. Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (London). 365:1993;652-654.
66. Sibley D.R. New insights into dopaminergic function using anti-sense and genetically altered animals. Ann. Rev. Pharmacol. & Toxicol. 39:1999;313-341.
67. Sidhu A., Sullivan M., Kohout T., Balen P., Fishman P. D-1 dopamine receptors can interact with both stimulatory and inhibitory G proteins. J. Neurochem. 57:1991;1445-1451.
68. z. J. Neurochem. 70:1998;2459-2467.
69. Sidhu A. Coupling of D-1 and D-5 dopamine receptors to multiple G proteins: implications for understanding the diversity in receptor/G protein coupling. Mol. Neurobiol. 16:1998;125-134.
70. Skaaning-Jensen B., Levavi-Sivan B., Fishburn C.S., Fuchs S. Functional expression of the murine D2, D3, and D4 dopamine receptors in Xenopus laevis oocytes. FEBS Lett. 420:1997;191-195.
71. Sugamori K. S., Hamadanizadeh S. A., Scheideler M. A., Hohlweg R., Vernier P. and Niznik H. B., Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012, J. Neurochem., 1998, 71, 1685-1693.
72. Surmeier D.J., Bargas J., Hemmings H.C. Jr, Nairn A.C., Greengard P. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron. 14:1995;385-397.
73. Tiberi M., Caron M.G. High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J. Biol. Chem. 269:1994;27925-27931.
74. Uh M., White B., Sidhu A. Altered association of agonist-activated renal D1A dopamine receptors with G proteins in proximal tubules of the SHR. J. Hypertens. 16:1998;1307-1313.
75. Undie A.S., Weinstock J., Sarua H.M., Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62:1994;2045-2048.
76. Waddington J.L., Lane A., Larkin C., O'Callaghan E. The neurodevelopmental basis of schizophrenia: clinical clues from cerebro-craniofacial dysmorphogenesis, and the roots of a lifetime trajectory of disease. Biol. Psychiatry. 46:1999;31-39.
77. i3c region. Mol. Pharmacol. 50:1996;351-358.
78. Watanabe M., Kodama T., Hikosaka K. Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J. Neurophysiol. 78:1997;2795-2798.
79. Watts V.J., Neve K.A. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Mol. Pharmacol. 52:1997;181-186.
80. Watts V.J., Wiens B.L., Cumbay M.G., Vu M.N., Neve R.L., Neve K.A. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. J. Neurosci. 18:1998;8692-8699.
81. White B.H., Kimura K., Sidhu A. Inhibition of hormonally induced inositol trisphosphate production in transfected GH4C1 cells: a novel role for the D5 subtype of the dopamine receptor. Neuroendocrinology. 69:1999;209-216.
82. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
83. Wolfe S.E., Morris S.J. Dopamine D2 receptor isoforms expressed in At-T20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J. Neurochem. 73:1999;2375-2382.
84. Wonerow P., Schoneberg T., Schultz G., Gudermann T., Paschke R. Deletions in the third intracellular loop of the thyrotropin receptor. A new mechanism for constitutive activation. J. Biol. Chem. 273:1998;7900-7905.
85. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediate behavioral responses. Cell. 79:1994;729-742.
86. t2) to inhibit forskolin-stimulated cAMP accumulation. J. Biol. Chem. 272:1997;16599-16602.